Allergy Vaccine Successful

27-Jan-2017 - Biomay announced that a second Phase IIb study has been successfully completed with its third generation grass pollen allergy vaccine BM32. The study was designed to demonstrate the optimal dose regimen to induce an allergen-specific IgG immune response. Correlation of the immunological effects ...

Zika & Chikungunya Vaccine Development Boosted By Cash Injection

Themis Bioscience successfully closed 10 Mio EUR financing round

30-Nov-2016 - Themis Bioscience successfully closed a Series B financing round of 10 Mio Euro. The fresh capital will be used to complete a phase 2 clinical trial of its lead product, a vaccine candidate against Chikungunya fever. Further products that will benefit include the company's Zika virus vaccine ...

Positive Phase IIB data for Biomay's grass pollen allergy vaccine

09-Jun-2015 - Biomay announced that the results of a landmark phase IIb study with its 3rd generation grass pollen allergy vaccine BM32 will be reported at the EAACI Congress 2015 in Barcelona, Spain. The study, which was completed in 2014, convincingly provided clinical proof of concept for this first of kind ...

Biomay reports positve Phase IIB data with grass pollen allergy vaccine

30-Jan-2015 - Biomay announced that a landmark Phase IIb study has been successfully completed with its 3rd generation grass pollen allergy vaccine BM32. The study was designed to show sustained alleviation of allergy symptoms over two consecutive grass pollen seasons.It was observed that the ...

EU support boosts development of vaccines against Parkinson's and Multiple System Atrophy

AFFiRiS leads consortium

30-Apr-2014 - An international consortium of top European research teams has received significant EU funding for the development of therapeutic vaccines against Parkinson's Disease (PD) and Multiple System Atrophy (MSA). Led by the Austrian biotech company AFFiRiS AG, the consortium will use a novel tandem ...

Biomay's grass pollen allergy vaccine shows efficacy in phase IIa trial

15-Jun-2012 - Biomay AG announced promising results from a First-in-Man Phase IIa trial with its allergy vaccine BM32. The vaccine significantly reduced allergy-related nasal symptoms in a study group of 70 patients suffering from grass pollen allergy. The environmental challenge study also showed that BM32 ...

First clinical trial for the Parkinson´s vaccine starts in Vienna

07-Jun-2012 - AFFiRiS AG announced the start of the Phase I study of its Parkinson´s vaccine candidate PD01A. This vaccine represents the first agent worldwide aiming at disease modification of Parkinson´s rather than addressing symptomatic improvement only. PD01A targets a protein called alpha-Synuclein ...

AFFiRiS' Alzheimer's Vaccine AD02 already in clinical phase II

27-Apr-2010 - AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the ...

Parkinson vaccination: Proof of Concept for AFFiRiS AG

06-Apr-2010 - AFFiRiS AG announced an important step forward in the development of its vaccine for Parkinson's disease. The vaccine, known as PD01, has undergone numerous preclinical tests which have confirmed its principle of action ("Proof of Concept"). The company is now starting to prepare for clinical ...

AFFiRiS: Vaccination against hypertension has been awarded an FFG grant up to EUR 1.2 million

01-Mar-2010 - AFFiRiS AG announced the start of a new program to develop a vaccine against hypertension. This means that there are now four of the company's current seven development projects in the public domain. The specific reason for the "outing" of project no. 4 was the approval of public research ...